ABPRO CORP (ABP NYSE) stock market data APIs
$0.4669
-0.03(-6%)
as of March 19, 2025
ABPRO CORP Financial Data Overview
Abpro Holdings, Inc., a biotechnology company, provides antibody therapeutics for cancer related issues. Its platform DiversImmune addresses the antibody therapeutics. The company's product candidates include ABP-102 for the treatment of breast and gastric cancer; and ABP-110 for the treatment of liver cancer. It also offers ABP-105 for the treatment of gastric cancer and ABP 201 for vascular diseases of the eye and diabetic macular edema. Abpro Holdings, Inc. was incorporated in 2004 and is based in Woburn, Massachusetts.
Prev. Close
0.5016
Open
0.4669
High
0.5602
Low
0.4669
52 wk Range
0.3839-13
Market Cap
27 022 K
Shares Outstanding
51 966 K
Revenue
230 K
Beta
-0.295
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ABPRO CORP data using free add-ons & libraries
Get ABPRO CORP Fundamental Data
ABPRO CORP Fundamental data includes:
- Net Revenue: 230 K
- EBITDA: -10 828 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ABPRO CORP News
New
Abpro Statement on the Departure of Former CEO Ian Chan
WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-t...
Abacus Property Group's (ASX:ABP) recent AU$133m market cap decline means a loss of AU$27k for insiders who bought this year
The recent price decline of 4.6% in Abacus Property Group's (ASX:ABP) stock may have disappointed insiders who bought AU$409k worth of shares at an average price of AU$3.56 in the past 12 months. Insi...
Abpro 建立策略合作夥伴關係以在亞洲市場推動兩個雙特異性抗體候選產品
Abpro 將獲得最多 11 億美元，其中包括 3,000 萬美元的前期股權投資、臨床資金、里程碑和特許權使用費 Abpro 授予前身為 Ugint Co. Ltd 的 Abpro Bio 獨家許可�...
Abpro Forms Strategic Partnership to Advance Two Bispecific Antibody Candidates in Asian Markets
Abpro to receive up to $1.1 billion, including a $30 million upfront equity investment, clinical funding, milestones, and royalties Abpro grants exclusive licenseto Abpro Bio, formerly named Ugint Co...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
